Compositions and methods relating to pooled fetal support tissue
Inventors
Tseng, Scheffer • Tan, Ek Kia • Chua, Lorraine
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein is a composition, methods comprising, pooled fetal support tissue, wherein the pooled fetal support tissue comprises a therapeutically effective amount of native HC-HA/PTX3 complex.
Core Innovation
The invention relates to a composition comprising pooled umbilical cord and amniotic membrane (MAU) tissue from a plurality of donors. The pooled MAU tissue is lyophilized and includes a native HC-HA/PTX3 (nHC-HA/PTX3) complex possessing therapeutic potency.
The disclosure addresses donor-to-donor variability by pooling MAU tissue from multiple donors to improve uniformity and potency of the resulting composition. It uses lyophilization for the pooled MAU tissue containing the native HC-HA/PTX3 complex and describes preservation of bioactive components together with increased stability and concentration.
Processing and characterization are described with assays measuring HA content, total protein, PTX3 content, and potency or functional outputs. Potency and functional assessment includes cell-based potency assays such as ODI-TRAP, NO, M2 macrophage polarization, and WST-1, with identity and acceptance based on HA content and potency or functional activity criteria.
Claims Coverage
The identified independent claim coverage centers on three inventive features: a pooled MAU composition from multiple donors, lyophilization of that composition, and enrichment for total protein relative to non-pooled MAU tissue.
Pooled MAU tissue from multiple donors with nHC-HA/PTX3 complex
A composition comprising pooled umbilical cord and amniotic membrane (MAU) tissue, wherein the pooled MAU tissue comprises MAU tissue from a plurality of donors, and wherein the lyophilized pooled MAU tissue comprises a native HC-HA/PTX3 (nHC-HA/PTX3) complex possessing therapeutic potency.
Lyophilized pooled MAU tissue
The pooled MAU tissue is lyophilized, such that the lyophilized pooled MAU tissue comprises the native HC-HA/PTX3 complex with therapeutic potency.
Total protein enrichment relative to non-pooled MAU tissue
The lyophilized pooled MAU tissue is enriched for total protein relative to non-pooled MAU tissue.
The claimed coverage is directed to a pooled MAU composition from multiple donors that is lyophilized and contains a native HC-HA/PTX3 complex with therapeutic potency, together with enrichment for total protein relative to non-pooled MAU tissue.
Stated Advantages
Reduced donor-to-donor variability compared with non-pooled MAU lots.
Improved uniformity and potency by pooling MAU tissue from multiple donors to mitigate donor-to-donor variability.
Maintains therapeutic potency of the nHC-HA/PTX3 complex after processing and lyophilization.
Preservation of bioactive components and increased stability and concentration through lyophilization of the pooled MAU tissue.
Improves consistency associated with preserved HA high molecular weight and maintained potency across pooled lots.
Therapeutically effective native HC-HA/PTX3 complex within the pooled lyophilized MAU composition.
Documented Applications
Treatment of degenerative disease.
Treatment of inflammation.
Wound healing, including complex wounds.
Osteoarthritis.
Ocular disorders including dry eye, ocular surface inflammation, and ulcerative keratitis.
Interested in licensing this patent?